Enesi Pharma Limited

Activities: Pharmaceutical

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Research & Development

Enesi Pharma and NIAID to test novel flu vaccines

The vaccines will be developed using Enesi Pharma’s ImplaVax technology
Ingredients

Enesi Pharma hits milestone in thermostable solid-dose live vaccines development

Enesi has achieved a key milestone in development of thermostable solid-dose live vaccines against measles and rubella
Drug Delivery

Enesi and Oxford Vaccine Group partner to immunise against plague

Collaboration aims to create an easy-to-use solid dose plague vaccine for use in areas of outbreak and as a defence against bioterrorism
Media

Needle-free vaccine collaboration for emergent threat pathogens

Enesi Pharma has entered a research and development collaboration with Public Health England
Pharmaceutical

Enesi welcomes global vaccine expert to Scientific Advisory Board
Subscribe now